


Lazuline Biotech sets up cell culture lab with BioNEST

17 July 2020 | News

The objective is to take up product testing and validation on different stem cell lines and other mammalian cells using the company's Human Serum Albumin



Hyderabad based Lazuline Biotech has established a cell culture laboratory in collaboration with BioNest (Bioincubators Nurturing Entrepreneurship for Scaling Technologies) at Hyderabad Central University, a Government of India Initiative as part of "Make in India".

The objective is to take up product testing and validation on different stem cell lines and other mammalian cells using the company's Human Serum Albumin (HSA) and continuous improvements to ensure its market positioning for global clients. This facility will be operational by the end of July 2020.

Lazuline Biotech is a research driven biotechnology company focused on developing innovative biosimilars. The company is one among the key players globally involved in the development and manufacturing of recombinant therapeutic proteins, antigens and enzymes that can positively disrupt the healthcare sector.

The company has developed recombinant Human Albumin using recombinant DNA technology - which is similar to traditional Human Serum Albumin (HSA) derived from human blood. Albumin is a protein produced by the liver that circulates in plasma, it is the body's predominant serum-binding protein. Albumin (or) HSA performs important functions like maintaining intravascular colloid osmotic pressure and transports therapeutic agents. Traditionally, HSA is derived from human blood, which has risks associated with low purity, inconsistency in quality, presence of pathogens and short supply.

"Lazuline recognises the need for an innovation that can replace the traditional process, hence with its focused research involving experienced team of world-renowned scientists has developed its flagship product Recombinant Human Albumin (rHSA) – rAlblaz - using -- Pichia Pastoris as expression host- Making rAlblaz highly preferred choice for its superiority in terms of higher purity, animal-origin free, consistent batch efficacy.

rHSA can help bridge the gap between the demand and supply of HSA that the healthcare sector has been grappling with for years. Given the current COVID situation, it has a key role to play as the blood availability has further come down for the blood derived protein, hence rHSA can be the safest and the most dependable alternative", said Dr. Ramesh Bhagam, Vice President- Quality & Regulatory, Lazuline Biotech, Hyderabad